ArticleCureus2026
Impact of Symptomatic Versus Asymptomatic Breast Cancer Recurrence on Survival: A Retrospective Study of 238 Patients.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The relationship between symptoms at breast cancer recurrence and post-recurrence survival remains poorly understood. This study aimed to evaluate factors influencing survival after recurrence based on the presence or absence of symptoms at the time of breast cancer recurrence. Methods We retrospectively reviewed the records of 238 patients diagnosed with the first distant recurrent breast cancer between January 2000 and December 2019. Post-recurrence survival was analyzed based on whether the first distant recurrence was symptomatic or asymptomatic and stratified by clinical and pathologic characteristics. Significant prognostic factors related to post-recurrence survival were identified. Results For the entire cohort, the median overall survival after recurrence was 2.06 years for symptomatic patients at recurrence and 3.58 years for asymptomatic patients at recurrence (p = 0.006). Among symptomatic patients at recurrence, those aged > 50 years, with positive lymph nodes, or with hormone receptor-positive/HER2-positive subtype exhibited significantly worse prognoses than those without symptoms at recurrence. In asymptomatic patients at recurrence, the first distant recurrence was detected significantly earlier using imaging modalities than using blood tests. Conclusion Symptom status at first distant breast cancer recurrence may be associated with post-recurrence survival, with asymptomatic recurrence showing more favorable outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.